[Corrigendum] Construction of the plasmid for expression of EGFP‑M‑IL‑2(88Arg, 125Ala) fusion protein and the anti‑tumor effects exerted by the fusion protein in HeLa-60 cells

• Authors:
  • Guangcan Shao
  • Dongmeng Qian
  • Haitao Wang
  • Zhiyong Yan
  • Ming Hu
  • Tongmei Wang
  • Bin Wang

• View Affiliations

  
  Affiliations: Department of Microbiology, Qingdao University Medical College, Qingdao, Shandong 266071, P.R. China
• Published online on: March 10, 2021     https://doi.org/10.3892/ol.2021.12623
• Article Number: 362

• Copyright : © Shao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article

Oncol Lett 9: [Related article:] 2729-2735, 2015; DOI: 10.3892/ol.2015.3125

Following the publication of the above article, an interested reader drew to the authors’ attention that the 24 h, A and the 48 h, C panels shown in Fig. 4 appeared to contain overlapping data. After having re-examined their original data, the authors have realized that this Figure was assembled incorrectly.

Figure 4. The morphology of various HeLa cell treatment groups were observed at 24, 48 and 72 h subsequent to transfection. (A) Cells transfected with pLEGFP-C1-M-IL-2(88Arg, 125Ala). (B) pLEGFP-C1-transfected cells. (C) Lipofectamine 2000-transfected cells. (D) non-transfected cells.

The corrected version of Fig. 4 is presented opposite. Note that this inadvertent error did not have a major impact on the results or the conclusions reported in this paper. Four of the named authors (Guangcan Shao, Dongmeng Qian, Ming Hu and Tongmei Wang) agree with this corrigendum; the other three authors proved to be uncontactable. These four authors would like to thank the Editor of Oncology Letters for allowing them the opportunity to publish this corrigendum; furthermore, they apologize to the readership of the Journal for any inconvenience caused.